INDENA SPOTLIGHTS EXPANDED CAPABILITIES AND INNOVATION AT CPHI 2025
INDENA SPOTLIGHTS EXPANDED CAPABILITIES AND INNOVATION AT CPHI 2025 FEATURING: NEXT – GENERATION TECHNOLOGIES
INDENA SPOTLIGHTS EXPANDED CAPABILITIES AND INNOVATION AT CPHI 2025 FEATURING: NEXT – GENERATION TECHNOLOGIES

THE COMPANIES COMBINE THEIR UNIQUE EXPERTISE TO ACCELERATE THE DEVELOPMENT OF INNOVATIVE, SUSTAINABLE PAYLOAD-LINKERS
Working with HPAPIs brings unique challenges in safety, containment, and scalability; challenges that Indena can face, being a global leader in development and production of high-quality and complex APIs and HPAPIs derived from plants, synthesis, sem

THE ITALIAN COMPANY STANDS AS A RELIABLE PARTNER FOR PHARMA AND BIOTECH CLIENTS IN
Indena is glad to attend CPHI Japan in Tokio 9 – 11 April 2025 and to meet its customers and stakeholders.
The market for HPAPIs is growing due to the increasing prevalence of complex diseases like cancers, autoimmune disorders, infectious diseases and rare diseases.
INDENA DISPLAYS A KEY UNIQUENESS ON HIGHLY POTENT APIS DOWN TO 1 NG/M3 OEL.
THE EXPERTISE INCLUDES PAYLOADS FOR ADCS, WITH A BACKWARD INTEGRATION ON FERMENTATION FOR TOXINS
REQUIRING THIS STEP AND LYOPHILIZATION ABILITY IN HIGH CONTAINMENT
Indena’s Custom Development & Manufacturing Organization services offer a full range of manufacturing capabilities for pharmaceutical ingredients including Active Pharmaceutical Ingredients (APIs). Such services include the extraction, isolation…
The CDMO area of business has been one of the priority for Indena’s strategic development for years. Recently, the company invested to implement new cutting-edge technologies, mainly for the expansion of the GMP pilot plant and the upgrade of the …
Highlights from our discussion with Stefano Togni, Chief Commercial Officer and Business Development Director at Indena.